Search company, investor...

Predict your next investment

Novartis company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
novartis.com

Investments

61

Portfolio Exits

34

Partners & Customers

10

Service Providers

1

About Novartis

Novartis (NYSE: NVS) researches, develops, manufactures, and markets healthcare products. It provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The company was founded in 1996 and is based in Basel, Switzerland.

Headquarters Location

Forum 1 Novartis Campus

Basel, 4056,

Switzerland

+41 61 324 11 11

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Expert Collections containing Novartis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Novartis in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Novartis News

JB Chemicals & Pharma - On M&A Spree To Diversify India Base: ICICI Securities

Dec 27, 2023

JB Chemicals & Pharmaceuticals Ltd. (Source: Company website) NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. ICICI Securities Report JB Chemicals and Pharmaceuticals Ltd. is licensing ophthalmic brands from Novartis, marking its foray in this therapy. It will make a cumulative payment of Rs 10.89 billion for in-licensing the 10 brands of Novartis for three years, post which it will get a perpetual license for those brands. Key acquired brands like Vigamax, Nevanac, Travatan are the market leaders in molecule category. As per IQVIA, sales from these 10 brands have registered a compound annual growth rate of 8% in the last two years. Management aims to grow the acquired portfolio at 15% in coming years by launching line extensions and adding 30- 40 MRs. We raise our FY25E earnings by 1% to factor in the impact of this deal. We maintain our 'Hold' rating on the stock but raise target price to Rs 1,595, valuing the company at 20 times FY26E enterprise value/Ebitda (earlier 20 times FY25E). Click on the attachment to read the full report: ICICI Securities- JB Chemicals and Pharma company update.pdf View Document

Novartis Investments

61 Investments

Novartis has made 61 investments. Their latest investment was in Flare Therapeutics as part of their Series B on March 22, 2023.

CBI Logo

Novartis Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/22/2023

Series B

Flare Therapeutics

$123M

Yes

6

1/14/2023

Series D - III

MaxOne

Yes

1

10/25/2022

Series B

Alto Neuroscience

$35M

Yes

9

10/19/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

8/25/2022

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/22/2023

1/14/2023

10/25/2022

10/19/2022

8/25/2022

Round

Series B

Series D - III

Series B

Series B

Series A - II

Company

Flare Therapeutics

MaxOne

Alto Neuroscience

Subscribe to see more

Subscribe to see more

Amount

$123M

$35M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

9

10

10

Novartis Portfolio Exits

34 Portfolio Exits

Novartis has 34 portfolio exits. Their latest portfolio exit was CELLforCURE on November 27, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/27/2023

Divestiture

$99M

2

10/4/2023

IPO

Sandoz

$99M

Public

3

6/30/2023

Divestiture

Novartis - Ophthalmology Business

$99M

2

8/25/2022

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

1/1/2022

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/27/2023

10/4/2023

6/30/2023

8/25/2022

1/1/2022

Exit

Divestiture

IPO

Divestiture

Spinoff / Spinout

Spinoff / Spinout

Companies

Sandoz
Novartis - Ophthalmology Business

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

2

3

2

10

10

Novartis Acquisitions

34 Acquisitions

Novartis acquired 34 companies. Their latest acquisition was Chinook Therapeutics on August 11, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/11/2023

Series B

$99M

$171M

Acq - P2P

8

7/17/2023

Series B

$99M

$111.2M

Acquired

6

6/12/2023

$99M

Acquired Unit

1

12/22/2021

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

9/21/2021

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

8/11/2023

7/17/2023

6/12/2023

12/22/2021

9/21/2021

Investment Stage

Series B

Series B

Other

Series A

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$171M

$111.2M

$99M

$99M

Note

Acq - P2P

Acquired

Acquired Unit

Subscribe to see more

Subscribe to see more

Sources

8

6

1

10

10

Novartis Partners & Customers

10 Partners and customers

Novartis has 10 strategic partners and customers. Novartis recently partnered with Jeil Pharmaceutical on December 12, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

12/11/2023

Licensee

South Korea

Jeil Pharm to exclusively supply Novartis' glaucoma and conjunctivitis treatments in Korea

`` Novartis will focus on the sales of retinal disease treatments , and glaucoma and allergy treatments through our partnership with Jeil Pharmaceutical , which has excellent competitiveness in hospitals , and will strive to provide patients and healthcare providers with a stable supply of ophthalmic products , '' Yoo added .

1

11/13/2023

Licensor

United States

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

These statements include , but are not limited to , statements relating to the anticipated completion of the proposed transaction with Novartis , potential payments that may be received by Legend Biotech Ireland Limited under the License Agreement , including for potential milestones and royalties , the ability of Legend Biotech Ireland Limited and Novartis to develop licensed product from clinic to market , the potential benefits of licensed product , the potential benefits from synergies of licensed product with the T-Charge ™ platform , and Legend Biotech Ireland Limited 's and Novartis ' rights and obligations under the License Agreement .

11

11/12/2023

Partner

Hungary

Novartis Hones its Innovation Focus in Hungary

That 's the context and why we were so excited about announcing this partnership between Novartis , the Ministry of Innovation , and Semmelweis University .

1

11/6/2023

Licensor

South Korea

Subscribe to see more

Subscribe to see more

10

10/30/2023

Partner

United Arab Emirates

Subscribe to see more

Subscribe to see more

10

Date

12/11/2023

11/13/2023

11/12/2023

11/6/2023

10/30/2023

Type

Licensee

Licensor

Partner

Licensor

Partner

Business Partner

Country

South Korea

United States

Hungary

South Korea

United Arab Emirates

News Snippet

Jeil Pharm to exclusively supply Novartis' glaucoma and conjunctivitis treatments in Korea

`` Novartis will focus on the sales of retinal disease treatments , and glaucoma and allergy treatments through our partnership with Jeil Pharmaceutical , which has excellent competitiveness in hospitals , and will strive to provide patients and healthcare providers with a stable supply of ophthalmic products , '' Yoo added .

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

These statements include , but are not limited to , statements relating to the anticipated completion of the proposed transaction with Novartis , potential payments that may be received by Legend Biotech Ireland Limited under the License Agreement , including for potential milestones and royalties , the ability of Legend Biotech Ireland Limited and Novartis to develop licensed product from clinic to market , the potential benefits of licensed product , the potential benefits from synergies of licensed product with the T-Charge ™ platform , and Legend Biotech Ireland Limited 's and Novartis ' rights and obligations under the License Agreement .

Novartis Hones its Innovation Focus in Hungary

That 's the context and why we were so excited about announcing this partnership between Novartis , the Ministry of Innovation , and Semmelweis University .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

11

1

10

10

Novartis Service Providers

1 Service Provider

Novartis has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Novartis Team

149 Team Members

Novartis has 149 team members, including current Chief Executive Officer, Vasant Narasimhan.

Name

Work History

Title

Status

Vasant Narasimhan

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Vasant Narasimhan

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Novartis to Competitors

B
Boehringer Ingelheim

Boehringer Ingelheim is a research-driven biopharmaceutical company. The company's main offerings include innovative therapies in areas of high unmet medical need, spanning three business areas: human pharma, animal health, and biopharmaceutical contract manufacturing. It primarily serves the pharmaceutical and healthcare industries. The company was founded in 1885 and is based in Ingelheim am Rhein, Germany.

Virta Health Logo
Virta Health

Virta Health develops a clinically proven treatment to prevent type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery. It offers evidence-based solutions and tools to help users lose weight, maintain blood sugar levels, and reduce unnecessary medications. It was formerly known as KetoThrive. The company was founded in 2014 and is based in San Francisco, California.

Ferring Pharmaceuticals Logo
Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group. Ferring Pharmaceuticals specializes in the areas of reproductive medicine and women’s health, urology and gastroenterology.

G
GI Innovation

GI Innovation is a bio-venture company that focuses on integrating basic science and translational innovation in the biologics sector. The company's main services include the development of biologics for immuno-oncology and inflammation/immunology diseases, utilizing their proprietary GI-SMART platform technology to optimize multi-targeting fusion protein therapeutics. The company primarily sells to the healthcare and pharmaceutical industries. It was founded in 2017 and is based in Seoul, South Korea.

N
Norstella

Norstella is a company that focuses on providing solutions in the pharmaceutical industry. The company offers a range of consultancy services and solutions, helping clients navigate the complexities of the drug development life cycle, from pipeline to patient. Norstella primarily serves the pharmaceutical industry. It is based in Morrisville, Pennsylvania.

I
Immunwork

Immunwork is a pharmaceutical company that focuses on the research, development, and commercialization of new drugs based on its technology platform for treating multiple types of cancer, autoimmune diseases, osteoporosis, and other severe clinical conditions.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.